BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 20837699)

  • 1. Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation.
    Huggenberger R; Ullmann S; Proulx ST; Pytowski B; Alitalo K; Detmar M
    J Exp Med; 2010 Sep; 207(10):2255-69. PubMed ID: 20837699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
    Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
    Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An important role of lymphatic vessel activation in limiting acute inflammation.
    Huggenberger R; Siddiqui SS; Brander D; Ullmann S; Zimmermann K; Antsiferova M; Werner S; Alitalo K; Detmar M
    Blood; 2011 Apr; 117(17):4667-78. PubMed ID: 21364190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice.
    Veikkola T; Jussila L; Makinen T; Karpanen T; Jeltsch M; Petrova TV; Kubo H; Thurston G; McDonald DM; Achen MG; Stacker SA; Alitalo K
    EMBO J; 2001 Mar; 20(6):1223-31. PubMed ID: 11250889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
    Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
    J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis.
    Guo R; Zhou Q; Proulx ST; Wood R; Ji RC; Ritchlin CT; Pytowski B; Zhu Z; Wang YJ; Schwarz EM; Xing L
    Arthritis Rheum; 2009 Sep; 60(9):2666-76. PubMed ID: 19714652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphangiogenesis-independent resolution of experimental edema.
    Ongstad EL; Bouta EM; Roberts JE; Uzarski JS; Gibbs SE; Sabel MS; Cimmino VM; Roberts MA; Goldman J
    Am J Physiol Heart Circ Physiol; 2010 Jul; 299(1):H46-54. PubMed ID: 20207821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the VEGFR-3 pathway by VEGF-C attenuates UVB-induced edema formation and skin inflammation by promoting lymphangiogenesis.
    Kajiya K; Sawane M; Huggenberger R; Detmar M
    J Invest Dermatol; 2009 May; 129(5):1292-8. PubMed ID: 19005491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.
    Roberts N; Kloos B; Cassella M; Podgrabinska S; Persaud K; Wu Y; Pytowski B; Skobe M
    Cancer Res; 2006 Mar; 66(5):2650-7. PubMed ID: 16510584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional analyses of the bone marrow kinase in the X chromosome in vascular endothelial growth factor-induced lymphangiogenesis.
    Jones D; Xu Z; Zhang H; He Y; Kluger MS; Chen H; Min W
    Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2553-61. PubMed ID: 20864667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins.
    Hong YK; Lange-Asschenfeldt B; Velasco P; Hirakawa S; Kunstfeld R; Brown LF; Bohlen P; Senger DR; Detmar M
    FASEB J; 2004 Jul; 18(10):1111-3. PubMed ID: 15132990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation.
    Karpanen T; Wirzenius M; Mäkinen T; Veikkola T; Haisma HJ; Achen MG; Stacker SA; Pytowski B; Ylä-Herttuala S; Alitalo K
    Am J Pathol; 2006 Aug; 169(2):708-18. PubMed ID: 16877368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.
    Pytowski B; Goldman J; Persaud K; Wu Y; Witte L; Hicklin DJ; Skobe M; Boardman KC; Swartz MA
    J Natl Cancer Inst; 2005 Jan; 97(1):14-21. PubMed ID: 15632376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues.
    Lohela M; Heloterä H; Haiko P; Dumont DJ; Alitalo K
    Am J Pathol; 2008 Dec; 173(6):1891-901. PubMed ID: 18988807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AIP1 mediates vascular endothelial cell growth factor receptor-3-dependent angiogenic and lymphangiogenic responses.
    Zhou HJ; Chen X; Huang Q; Liu R; Zhang H; Wang Y; Jin Y; Liang X; Lu L; Xu Z; Min W
    Arterioscler Thromb Vasc Biol; 2014 Mar; 34(3):603-15. PubMed ID: 24407031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin.
    Liu ZY; Qiu HO; Yuan XJ; Ni YY; Sun JJ; Jing W; Fan YZ
    Int J Oncol; 2012 Nov; 41(5):1762-72. PubMed ID: 22922710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic inflammation, lymphangiogenesis, and effect of an anti-VEGFR therapy in a mouse model and in human patients with aspiration pneumonia.
    Nihei M; Okazaki T; Ebihara S; Kobayashi M; Niu K; Gui P; Tamai T; Nukiwa T; Yamaya M; Kikuchi T; Nagatomi R; Ebihara T; Ichinose M
    J Pathol; 2015 Mar; 235(4):632-45. PubMed ID: 25348279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphangiogenic growth factors, receptors and therapies.
    Lohela M; Saaristo A; Veikkola T; Alitalo K
    Thromb Haemost; 2003 Aug; 90(2):167-84. PubMed ID: 12888864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis.
    Björndahl MA; Cao R; Burton JB; Brakenhielm E; Religa P; Galter D; Wu L; Cao Y
    Cancer Res; 2005 Oct; 65(20):9261-8. PubMed ID: 16230387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.